Drug Trial Radar · NCT05443685
ADX-629 Therapy for Sjogren-Larsson Syndrome
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 2, 2023
Primary completion
Apr 1, 2026
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- University of NebraskaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study will determine whether orally administered ADX-629 is safe and has biochemical efficacy in participants with Sjögren-Larsson syndrome (SLS), a rare inherited disorder of fatty aldehyde metabolism The disease is caused by bi-allelic mutations in ALDH3A2, which results in deficient activity of fatty aldehyde dehydrogenase (FALDH) and leads to the build-up of harmful long-chain (C16-C20) aldehydes and alcohols. Accumulation of these lipids and their metabolic products in skin, brain and eyes is responsible for the symptoms, which persist lifelong. ADX-629 is an aldehyde trapping agent that is expected to eliminate fatty aldehydes and negate aldehyde toxicity, improve the biochemical abnormalities and have clinical efficacy for SLS. The primary objective of this clinical protocol is to determine whether ADX-629 is safe and tolerable for use in SLS subjects. The secondary objective is to determine the efficacy of ADX-629 in reversing the biochemical abnormalities in SLS. Exploratory objectives are to evaluate the short-term clinical effects of ADX-629 on neurologic, cutaneous and ophthalmologic disease in SLS. Participants will be treated with ADX-629 for 12 weeks and monitored for safety and biochemical efficacy.
Conditions
- Sjogren-Larsson Syndrome
Interventions
ADX-629Drug
Particpants 10-50 years old will be administered ADX-629 250 mg tablets twice daily. Participants 5-9 years old will be administered ADX-629 125 mg tablets twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: weekly for 12 weeks
- Number of Participants With Abnormal Drug-related Safety Blood TestsTime frame: monthly for 12 weeks
- Compliance and Tolerability of ADX-629Time frame: daily for 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Nebraska Medical Center
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.